IGF1R and non-small cell lung carcinoma: For example, a cohort that combined Figitumumab, a monoclonal antibody targeting IGF-1R, with paclitaxel and carboplatin to combat advanced NSCLC generated greater progression-free survival in patients with squamous cell carcinoma during phase 2 trials, but increased deaths of subjects in phase 3 trials.